<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20250525065887N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-05-28</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of safety and efficacy of propofol/fentanyl in pediatrics emergency department</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of safety and efficacy of propofol/fentanyl and midazolam/fentanyl for procedural sedation</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-06-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>84</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/83788</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The randomization method used in this study will be stratified block randomization. Patients will be stratified based on key characteristics such as age, gender, and ASA, and then randomly assigned to study groups using a block size of 4, generated by random allocation software. The random sequence will be created using a random number generator within the software, and the allocation list will be prepared in advance by an independent person not involved in the study implementation or outcome assessment. For allocation concealment, sealed, opaque, and sequentially numbered envelopes will be used. These envelopes will be opened only by the person enrolling the patient, right at the point of assignment, Blinding description: This study will be a single-blind trial. In this context, single-blinding means that the participants (patients and their parents) will not be aware of the specific drug combination administered (either propofol/fentanyl or midazolam/fentanyl). Due to the visible differences between the drugs and the necessity of ensuring medication safety, the administering physician will be aware of the drug type. However, the responsibility for evaluating outcome variables such as pain, distress, depth of sedation, and documentation of adverse events will lie with an independent observer (a trained nurse) who will be blinded to the group allocation.</study_design>
      <phase>2</phase>
      <hc_freetext>Condition 1: Patients requiring LP. Condition 2: Patients requiring intubation. Condition 3: Patients with limb dislocation or fracture.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In the first intervention group, intravenous fentanyl (1–2 micrograms per kilogram) will be administered first, followed by slow intravenous administration of propofol (1–2 milligrams per kilogram). If the procedure is prolonged or if analgesia or sedation is inadequate, additional doses of fentanyl (1 microgram per kilogram) and propofol (0.5 milligrams per kilogram) will be administered. Intervention 2: Intervention group: In the second intervention group, intravenous midazolam (0.05–0.1 milligrams per kilogram) will be administered first, followed by slow intravenous administration of fentanyl (1–2 micrograms per kilogram). If the procedure is prolonged or if analgesia or sedation is inadequate, additional doses of fentanyl (1 microgram per kilogram) and midazolam (0.05 milligrams per kilogram) will be administered.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All demographic and clinical data collected from patients in the present study will be shared after de-identification.

When:
Access to the data will begin following the publication of the study results in the form of a scientific article.

To whom:
The data will be openly accessible to the public.

Conditions:
Data aggregation for multicenter studies will be possible upon request to the clinical trial coordinator (Dr. Kourosh Soltaniyeh Zanjani) and approval by the research team.

Where to obtain:
To access the study data, please contact the clinical trial coordinator, Dr. Kourosh Soltaniyeh Zanjani, via email at kouroshsoltaniye@gmail.com.

How to obtain:
Any requests regarding the research or industrial use of the data will be reviewed by the clinical trial coordinator and the research team and will be answered within seven working days.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Kourosh Soltaniyeh Zanjani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Mofid Children's Hospital, Shariati Ave, Tehran, Iran.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1546815514</zip>
        <telephone>+98 21 2290 4603</telephone>
        <email>kouroshsoltaniye@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Kourosh Soltaniyeh Zanjani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Mofid Children's Hospital, Shariati Ave, Tehran, Iran.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1546815514</zip>
        <telephone>+98 21 2290 4603</telephone>
        <email>kouroshsoltaniye@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Children aged 3 months to 18 years who are referred to the emergency department of Mofid Children’s Hospital
Patients who require procedural sedation</inclusion_criteria>
      <agemin>3 months</agemin>
      <agemax>18 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients with hemodynamic instability
Patients with a history of cardiac diseases
Children with known allergies to the study medications
Children with allergies to eggs or soy
Children classified as ASA physical status class 5 (high anesthesia risk)</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G97.1</hc_code>
      <hc_code>J98.9</hc_code>
      <hc_code>T14.3</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other reaction to spinal and lumbar puncture</hc_keyword>
      <hc_keyword>Respiratory disorder, unspecified</hc_keyword>
      <hc_keyword>Dislocation, sprain and strain of unspecified body region</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In the first intervention group, intravenous fentanyl (1–2 micrograms per kilogram) will be administered first, followed by slow intravenous administration of propofol (1–2 milligrams per kilogram). If the procedure is prolonged or if analgesia or sedation is inadequate, additional doses of fentanyl (1 microgram per kilogram) and propofol (0.5 milligrams per kilogram) will be administered.</i_keyword>
      <i_keyword>Intervention group: In the second intervention group, intravenous midazolam (0.05–0.1 milligrams per kilogram) will be administered first, followed by slow intravenous administration of fentanyl (1–2 micrograms per kilogram). If the procedure is prolonged or if analgesia or sedation is inadequate, additional doses of fentanyl (1 microgram per kilogram) and midazolam (0.05 milligrams per kilogram) will be administered.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Successful completion of the procedure. Timepoint: After the intervention. Method of measurement: "Success or failure of the procedure (which may include suturing, limb casting, lumbar puncture, intubation, etc.)".</prim_outcome>
      <prim_outcome>Patient recovery time after sedation. Timepoint: After the intervention. Method of measurement: Measurement of the time interval between the administration of the last dose of sedative medication and the point at which the patient is deemed ready for discharge from the emergency department based on post-sedation discharge criteria.</prim_outcome>
      <prim_outcome>Procedural distress. Timepoint: After the intervention. Method of measurement: To assess procedural distress in patients, the Observational Scale of Behavioral Distress (OSBD) will be used by an independent observer (a trained nurse from the emergency department). This scale is utilized to evaluate the level of behavioral distress in children under 18 years of age undergoing medical interventions.</prim_outcome>
      <prim_outcome>Depth of sedation. Timepoint: After the intervention. Method of measurement: The Ramsay Sedation Scale will be used to assess the depth of sedation.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-04-29</approval_date>
        <contact_name>Ethics committee of Shahid Beheshti University of Medical Sciences</contact_name>
        <contact_address>Shahid Beheshti University of Medical Sciences, Daneshjoo Blvd, Velenjac,Tehran, Iran. Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
